hotspot -WSS

hotspot

author：leisure time 2025-09-30 14:57:49 - browse：33658

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Wegovy leads to weight loss. Can it treat depression, too?

hotspot

WSS

Why Medicare shouldn’t cover every FDA

FDA's naming rule on biosimilars has undermined competition

Abortion pill case raises question: who can sue the FDA?

Abortion pill Supreme Court ruling could impact entire drug industry

Primary care physicians play key roles in Alzheimer's management

Why the world’s most expensive drug might be worth the price

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Why Medicare shouldn’t cover every FDA

ChatGPT in medicine: STAT answers readers' burning questions

White House pharmacy plagued with problems, investigation finds

What does generative AI mean for health care? We asked experts

Zyn nicotine pouches become unlikely player in latest culture war

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Will generative AI in health care meet the fate of IBM's Dr. Watson?

In Memoriam: Notable people who died in 2023

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

Abortion pill case raises question: who can sue the FDA?

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Syphilis numbers in the United States reach record heights

Patient advocates debate FDA's accelerated approval process

hotspot

hotspot

hotspot

knowledge